109 related articles for article (PubMed ID: 30865923)
1. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
Dinan MA; Wilson LE; Reed SD
J Natl Compr Canc Netw; 2019 Mar; 17(3):245-254. PubMed ID: 30865923
[TBL] [Abstract][Full Text] [Related]
2. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
3. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
Wilson LE; Pollack CE; Greiner MA; Dinan MA
Breast Cancer Res Treat; 2018 Jul; 170(2):361-371. PubMed ID: 29536319
[TBL] [Abstract][Full Text] [Related]
4. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
[TBL] [Abstract][Full Text] [Related]
5. Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption.
Dinan MA; Wilson LE; Reed SD; Griggs JJ; Norton EC
Clin Breast Cancer; 2020 Dec; 20(6):487-494.e1. PubMed ID: 32653473
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.
Epstein AJ; Wong YN; Mitra N; Vachani A; Hin S; Yang L; Smith-McLallen A; Armstrong K; Groeneveld PW
J Clin Oncol; 2015 Dec; 33(36):4259-67. PubMed ID: 26598749
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
8. Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
Mariotto A; Jayasekerea J; Petkov V; Schechter CB; Enewold L; Helzlsouer KJ; Feuer EJ; Mandelblatt JS
J Natl Cancer Inst; 2020 Feb; 112(2):154-160. PubMed ID: 31165854
[TBL] [Abstract][Full Text] [Related]
9. Real-world economic value of a 21-gene assay in early-stage breast cancer.
Waintraub SE; McNamara D; Graham DMA; Pecora AL; Min J; Wu T; Noh HG; Connors J; Pe Benito R; Choi K; Schultz E; Goldberg SL
Am J Manag Care; 2017 Dec; 23(12):e416-e420. PubMed ID: 29261249
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic outcomes associated with adjuvant chemotherapy in elderly patients with early stage operable breast cancer.
Sail KR; Franzini L; Lairson DR; Du XL
Value Health; 2012 Jan; 15(1):72-80. PubMed ID: 22264974
[TBL] [Abstract][Full Text] [Related]
11. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
[TBL] [Abstract][Full Text] [Related]
12. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.
Dzimitrowicz H; Mougalian S; Storms S; Hurd S; Chagpar AB; Killelea BK; Horowitz NR; Lannin DR; Harigopal M; Hofstatter E; DiGiovanna MP; Adelson KB; Silber A; Abu-Khalaf M; Chung G; Zaheer W; Abdelghany O; Hatzis C; Pusztai L; Sanft TB
J Oncol Pract; 2017 Dec; 13(12):e1012-e1020. PubMed ID: 29048991
[TBL] [Abstract][Full Text] [Related]
13. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011.
Su KW; Hall J; Soulos PR; Abu-Khalaf MM; Evans SB; Mougalian SS; Rutter CE; Davidoff AJ; Gross CP
J Geriatr Oncol; 2016 Jan; 7(1):15-23. PubMed ID: 26704661
[TBL] [Abstract][Full Text] [Related]
14. Comparison of treatment of early-stage breast cancer among Nurses' Health Study participants and other Medicare beneficiaries.
Austin AM; Kapadia NS; Brooks GA; Onega TL; Eliassen AH; Tamimi RM; Holmes M; Wang Q; Grodstein F; Tosteson ANA
Breast Cancer Res Treat; 2019 Apr; 174(3):759-767. PubMed ID: 30607634
[TBL] [Abstract][Full Text] [Related]
15. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
[No Abstract] [Full Text] [Related]
16. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
17. Association between adjuvant chemotherapy and risk of acute kidney injury in elderly women diagnosed with early-stage breast cancer.
Li S; Liu J; Virnig BA; Collins AJ
Breast Cancer Res Treat; 2017 Feb; 161(3):515-524. PubMed ID: 27933451
[TBL] [Abstract][Full Text] [Related]
18. 21-Gene Recurrence Score Testing in HER2-positive Patients.
Altman AM; Marmor S; Tuttle TM; Hui JYC
Clin Breast Cancer; 2019 Apr; 19(2):126-130. PubMed ID: 30595493
[TBL] [Abstract][Full Text] [Related]
19. Esophageal cancer treatment costs by phase of care and treatment modality, 2000-2013.
Tramontano AC; Chen Y; Watson TR; Eckel A; Hur C; Kong CY
Cancer Med; 2019 Sep; 8(11):5158-5172. PubMed ID: 31347306
[TBL] [Abstract][Full Text] [Related]
20. Costs of breast cancer recurrence after initial treatment for HR+, HER2-, high-risk early breast cancer: estimates from SEER-Medicare linked data.
Vitko AS; Martin P; Zhang S; Johnston A; Ohsfeldt R; Zheng S; Liepa AM
J Med Econ; 2024; 27(1):84-96. PubMed ID: 38059275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]